1. P08.01 Low-dose checkpoint inhibitors with hyperthermia and IL-2 are safe and effective in stage IV cancer with unfavorable immunological profile (MSIlow, PD-L1 under 1%, TMBlow) – A single-institution experience from 2015 to 2020. (1st October 2020) Authors: Kleef, R; Nagy, R; Bacher, V; Bakacs, T; Lausch, T; McKee, D; Moss, R; Bojar, H; Thoennissen, N Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗